Working… Menu

CAN008 Biomarker CD95 Ligand and CpG2 Methylation in Chinese Patients With Glioblastoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03152708
Recruitment Status : Unknown
Verified September 2017 by CANbridge Life Sciences Ltd..
Recruitment status was:  Not yet recruiting
First Posted : May 15, 2017
Last Update Posted : September 21, 2017
Information provided by (Responsible Party):
CANbridge Life Sciences Ltd.

Brief Summary:
This study was conducted on the post-operative tumor tissues from 62 GBM patients. 20 slices are necessary for all the CD95 and CpG2 test in the central lab by the methods of immunisation and DNA methylation.

Condition or disease

Layout table for study information
Study Type : Observational
Estimated Enrollment : 62 participants
Observational Model: Other
Time Perspective: Retrospective
Official Title: The Exploratory Study on CAN008 Biomarker CD95 Ligand and Its Promoter (CpG2) Methylation in Chinese Patients With Glioblastoma
Estimated Study Start Date : November 1, 2017
Estimated Primary Completion Date : December 1, 2017
Estimated Study Completion Date : December 31, 2017

Resource links provided by the National Library of Medicine

Primary Outcome Measures :
  1. CD95 Ligand Positive Rate [ Time Frame: 0 day ]

Secondary Outcome Measures :
  1. CpG2 Positive Rate [ Time Frame: 0 day ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Chinese GBM patients

Inclusion Criteria:

  • Chinese nationality
  • No limits on Gender and age
  • First diagnosed GBM
  • Brain tumor tissue cytological diagnosis of glioblastoma (GBM, pleomorphic glioblastoma, WHO level IV)

Exclusion Criteria:

  • Other types of glioma by histological diagnosis
  • Tumor tissue not eligible for the central laboratory testing standard
  • No enough tumor tissue for the central laboratory test

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03152708

Layout table for location contacts
Contact: Jack Hou 00862152996609

Sponsors and Collaborators
CANbridge Life Sciences Ltd.
Layout table for investigator information
Principal Investigator: Jinsong Wu, MD Huashan Hospital
Layout table for additonal information
Responsible Party: CANbridge Life Sciences Ltd. Identifier: NCT03152708    
Other Study ID Numbers: CAN-B1-008-L-009
First Posted: May 15, 2017    Key Record Dates
Last Update Posted: September 21, 2017
Last Verified: September 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue